Insulin and Oral Hypoglycemic Agents Indian Medical PG Practice Questions and MCQs
Practice Indian Medical PG questions for Insulin and Oral Hypoglycemic Agents. These multiple choice questions (MCQs) cover important concepts and help you prepare for your exams.
Insulin and Oral Hypoglycemic Agents Indian Medical PG Question 1: Which of the following statements about acarbose is incorrect?
- A. It is an alpha-glucosidase inhibitor.
- B. It does not delay the progression of diabetes. (Correct Answer)
- C. Controls both pre and post prandial hyperglycemia.
- D. It decreases fibrinogen levels.
Insulin and Oral Hypoglycemic Agents Explanation: Phase 1: it does not delay the progression of diabetes
- This statement is **incorrect** - clinical studies, particularly the **STOP-NIDDM trial**, have demonstrated that acarbose **can delay the progression from impaired glucose tolerance (IGT) to type 2 diabetes**.
- Acarbose's mechanism of reducing postprandial glucose fluctuations helps in **beta-cell preservation** and improves insulin sensitivity, thereby modifying disease progression.
- This is a well-established benefit of acarbose beyond just glycemic control.
*It is an alpha-glucosidase inhibitor*
- This is a **correct** statement - acarbose is indeed an **alpha-glucosidase inhibitor** that works in the small intestine [1].
- It inhibits enzymes that break down complex carbohydrates, thereby delaying glucose absorption and reducing postprandial glucose spikes [1], [3].
*It decreases fibrinogen levels*
- While acarbose does not have a **direct, primary pharmacological effect** on fibrinogen levels, this statement is debatable.
- Improved glycemic control with any antidiabetic agent can have indirect effects on various cardiovascular markers over time.
- However, decreasing fibrinogen is not a recognized clinical indication or primary mechanism of acarbose [2].
*Controls both pre and post prandial hyperglycemia*
- This is largely **correct** - acarbose is most effective at controlling **postprandial hyperglycemia** by delaying carbohydrate digestion and absorption [3].
- While its primary and strongest effect is on post-meal glucose spikes, improved overall glycemic control can contribute to modest improvements in fasting glucose levels as well.
Insulin and Oral Hypoglycemic Agents Indian Medical PG Question 2: Mechanism of action of teduglutide in short bowel syndrome:
- A. GLP-2 analog that inhibits apoptosis (Correct Answer)
- B. HT1A inhibitor
- C. C-peptide analog
- D. GLP-1 analog that inhibits apoptosis
Insulin and Oral Hypoglycemic Agents Explanation: ***GLP-2 analog that inhibits apoptosis***
- **Teduglutide** is a synthetic analog of **glucagon-like peptide-2 (GLP-2)**, which is a naturally occurring human hormone [1].
- Its primary mechanism in **short bowel syndrome** involves promoting mucosal growth and inhibiting epithelial cell apoptosis, thereby enhancing nutrient absorption and gut adaptation.
*GLP-1 analogs that inhibits apoptosis*
- **GLP-1 analogs** like exenatide or liraglutide are primarily used for **type 2 diabetes mellitus** to stimulate insulin secretion and suppress glucagon [2].
- While they can have some effects on gut motility, their main role is not in promoting mucosal growth or inhibiting apoptosis in the context of short bowel syndrome.
*HT1A inhibitor*
- **HT1A inhibitors** (5-HT1A receptor antagonists) are typically involved in modulating serotonin pathways, often with applications in conditions like **anxiety** or **depression**.
- There is no known direct link between HT1A inhibition and the treatment of short bowel syndrome.
*C-peptide analogs*
- **C-peptide** is a byproduct of insulin production and has been studied for potential roles in preventing diabetes complications, particularly in relation to **microvascular complications** [3], [4].
- It does not play a direct role as a therapeutic agent for promoting intestinal adaptation or inhibiting apoptosis in short bowel syndrome.
Insulin and Oral Hypoglycemic Agents Indian Medical PG Question 3: In a patient with hypoglycemia, what is the appropriate dose adjustment of insulin?
- A. Increase insulin dosage
- B. Decrease insulin dosage (Correct Answer)
- C. Maintain current insulin dosage
- D. Add a different medication
Insulin and Oral Hypoglycemic Agents Explanation: ***Decrease insulin dosage***
- Hypoglycemia indicates that the current insulin dose is too high, causing blood glucose levels to drop excessively [1].
- Reducing the insulin dosage helps prevent future episodes of low blood sugar by allowing blood glucose to remain within a healthier range [1].
*Increase insulin dosage*
- Increasing insulin would further lower blood glucose, exacerbating the **hypoglycemia** and potentially leading to a more severe and dangerous state.
- This action is appropriate for **hyperglycemia**, not hypoglycemia.
*Maintain current insulin dosage*
- Maintaining the current dose would not address the problem, as it has already proven to be too much for the patient, causing the **hypoglycemic episodes** [1].
- This approach would leave the patient at continued risk for recurrent hypoglycemia.
*Add a different medication*
- While other medications might be used in diabetes management, adding a new one without adjusting the existing insulin dose could further complicate blood glucose control.
- The immediate and most direct action for **hypoglycemia** caused by insulin is to adjust the insulin itself [1].
Insulin and Oral Hypoglycemic Agents Indian Medical PG Question 4: Insulin acts through which receptor?
- A. GPCR
- B. Enzyme-linked (Correct Answer)
- C. Intracellular
- D. Ion channel
Insulin and Oral Hypoglycemic Agents Explanation: ***Enzyme-linked***
- Insulin binds to an **enzyme-linked receptor**, specifically a **receptor tyrosine kinase**, to initiate its cellular effects.
- Upon binding, the receptor undergoes **autophosphorylation** and then phosphorylates intracellular substrate proteins, leading to a cascade of metabolic actions.
*GPCR*
- **G protein-coupled receptors (GPCRs)** are integral membrane proteins that, upon ligand binding, activate intracellular G proteins, transmitting signals through second messengers.
- Hormones like **glucagon** and **epinephrine** commonly act via GPCRs, not insulin.
*Intracellular*
- **Intracellular receptors** are typically found in the cytoplasm or nucleus and are activated by small, lipid-soluble ligands that can pass through the cell membrane, such as **steroid hormones**.
- Insulin is a large peptide hormone and cannot readily cross the cell membrane to act on intracellular receptors.
*Ion channel*
- **Ion channel receptors** are transmembrane proteins that open or close an ion channel in response to ligand binding, leading to changes in membrane potential or ion concentration.
- Neurotransmitters like **acetylcholine** often act on ligand-gated ion channels, which is not the mechanism of action for insulin.
Insulin and Oral Hypoglycemic Agents Indian Medical PG Question 5: Which of the following is FALSE about insulin action?
- A. Insulin promotes glycolysis
- B. Insulin promotes ketogenesis (Correct Answer)
- C. Insulin promotes glycogen synthesis
- D. Insulin promotes lipogenesis
Insulin and Oral Hypoglycemic Agents Explanation: ***Insulin promotes ketogenesis***
- Insulin is an **anabolic hormone** that works to prevent excessive **fat breakdown** and the formation of **ketone bodies**.
- High insulin levels actively **inhibit** enzymes involved in ketogenesis, such as **carnitine palmitoyltransferase-1 (CPT1)**, thereby reducing the transport of fatty acids into mitochondria for oxidation.
*Insulin promotes glycolysis*
- Insulin stimulates **glycolysis**, particularly in the liver and muscle, by increasing the activity of key enzymes like **glucokinase** and **phosphofructokinase-1**.
- This promotes the breakdown of glucose for **energy production** and provides substrates for fat synthesis.
*Insulin promotes glycogen synthesis*
- Insulin is a primary regulator of **glycogen synthesis** in the liver and muscles.
- It activates **glycogen synthase** and inhibits glycogen phosphorylase, thereby shunting glucose towards storage as **glycogen**.
*Insulin promotes lipogenesis*
- Insulin promotes **lipogenesis** (fat synthesis) in adipose tissue and liver.
- It increases glucose uptake into adipocytes and stimulates enzymes like **acetyl-CoA carboxylase** and **fatty acid synthase**, converting excess carbohydrates into fatty acids and subsequently **triglycerides**.
Insulin and Oral Hypoglycemic Agents Indian Medical PG Question 6: What is the primary effect of GLP-1 on insulin secretion?
- A. Increased aldosterone secretion by adrenal
- B. Increased PTH secretion
- C. Increased insulin secretion from beta-cells of pancreas (Correct Answer)
- D. Increased testosterone secretion from Leydig cells
Insulin and Oral Hypoglycemic Agents Explanation: ***Increased insulin secretion from beta-cells of pancreas***
- **Glucagon-like peptide-1 (GLP-1)** is an **incretin hormone** that stimulates **glucose-dependent insulin secretion** from pancreatic beta-cells.
- This effect is crucial for maintaining **glucose homeostasis**, especially after a meal.
*Increased aldosterone secretion by adrenal*
- **Aldosterone secretion** is primarily regulated by the **renin-angiotensin-aldosterone system (RAAS)** and potassium levels, not directly by GLP-1.
- Aldosterone's main function is to regulate **sodium and water balance** and **blood pressure**.
*Increased PTH secretion*
- **Parathyroid hormone (PTH)** secretion is primarily regulated by **serum calcium levels**.
- Its main role is to maintain **calcium homeostasis** by affecting bone, kidney, and intestine.
*Increased testosterone secretion from Leydig cells*
- **Testosterone secretion** from Leydig cells is primarily regulated by **luteinizing hormone (LH)** from the pituitary gland.
- GLP-1 has no direct significant role in **gonadal steroidogenesis**.
Insulin and Oral Hypoglycemic Agents Indian Medical PG Question 7: A 50-year-old woman, who is 5 feet 7 inches tall and weighs 185 pounds, has a family history of diabetes mellitus. Her fasting blood glucose levels are 160 mg/dL and 155 mg/dL on two occasions, and her HbA1c level is 7.9%. After being educated on medical nutrition therapy, she returns for reevaluation in 8 weeks, reporting that she has followed diet and exercise recommendations, but her fasting blood glucose levels remain between 140 and 150 mg/dL, and her HbA1c level is 7.7%. She is asymptomatic, and physical examination reveals no abnormalities. Which of the following treatments is the most appropriate for her condition?
- A. Metformin (Correct Answer)
- B. A thiazolidinedione
- C. A dipeptidyl peptidase-4 (DPP-4) inhibitor
- D. Insulin therapy
Insulin and Oral Hypoglycemic Agents Explanation: ***Metformin***
- **Metformin** is the **first-line pharmacological treatment** for type 2 diabetes mellitus when lifestyle modifications are insufficient, as seen in this patient whose blood glucose and HbA1c remain elevated after 8 weeks of diet and exercise [1].
- It works by **decreasing hepatic glucose production** and **improving insulin sensitivity**, and it has a favorable safety profile, including no risk of hypoglycemia and potential for weight neutrality or modest weight loss [1].
*A thiazolidinedione*
- **Thiazolidinediones** (e.g., pioglitazone) are effective in improving insulin sensitivity but are typically considered **second-line agents** or used in patients who cannot tolerate metformin.
- They are associated with side effects such as **weight gain**, **fluid retention**, and an increased risk of heart failure, which might not be ideal for initial therapy.
*A dipeptidyl ppetidase-4 (DPP-4) inhibitor*
- **DPP-4 inhibitors** (e.g., sitagliptin) enhance insulin secretion and suppress glucagon secretion in a glucose-dependent manner, offering good glycemic control with a low risk of hypoglycemia.
- However, they are **less potent** than metformin in lowering HbA1c and are generally used as **second-line therapy** or in combination with metformin.
*Insulin therapy*
- **Insulin therapy** is indicated for patients with **markedly elevated glucose levels** (e.g., HbA1c > 10% or fasting plasma glucose > 250 mg/dL), significant symptoms of hyperglycemia, or when other oral agents have failed.
- This patient's HbA1c of 7.7% and asymptomatic status suggest that oral agents should be attempted first before resorting to insulin.
Insulin and Oral Hypoglycemic Agents Indian Medical PG Question 8: Which of the following statements about nateglinide is correct?
- A. It is a long-acting oral hypoglycemic drug
- B. It can be used in patients with renal impairment with caution.
- C. It acts by blocking K+ channels in pancreatic beta-cells.
- D. Taken just before a meal, it limits postprandial hyperglycemia in type 2 diabetes mellitus (Correct Answer)
Insulin and Oral Hypoglycemic Agents Explanation: ***Correct: Taken just before a meal, it limits postprandial hyperglycemia in type 2 diabetes mellitus***
- **Nateglinide** is a **meglitinide analog** designed to stimulate rapid, short-duration insulin release
- Specifically taken **just before meals** (preprandially) to manage postprandial glucose spikes
- Its **rapid onset** (within 20 minutes) and **short duration** (approximately 4 hours) make it ideal for controlling **postprandial hyperglycemia** in type 2 diabetes
- This is the **primary clinical indication** and most characteristic feature of nateglinide
*Incorrect: It is a long-acting oral hypoglycemic drug*
- Nateglinide is actually a **short-acting** oral hypoglycemic, not long-acting
- Peak action occurs within **1 hour** and duration is only **3-4 hours**
- This short duration distinguishes it from sulfonylureas like **glimepiride** or **glibenclamide** which have longer durations
*Incorrect: It can be used in patients with renal impairment with caution*
- Nateglinide is **hepatically metabolized** but its metabolites are **renally excreted**
- Requires **dose adjustment** in moderate to severe renal impairment (CrCl <30 mL/min)
- **Repaglinide** (another meglitinide) is preferred in renal impairment due to predominantly biliary excretion
- Not the safest or most characteristic feature of nateglinide
*Incorrect: It acts by blocking K+ channels in pancreatic beta-cells*
- While nateglinide does **close ATP-dependent K+ channels** on pancreatic beta-cells (leading to depolarization and insulin release), this mechanism is **shared by all sulfonylureas and meglitinides**
- This is not a **distinguishing feature** of nateglinide specifically
- The question asks what is correct "about nateglinide" - while mechanistically true, this doesn't distinguish it from other insulin secretagogues
Insulin and Oral Hypoglycemic Agents Indian Medical PG Question 9: Exenatide is a new drug used in diabetes mellitus. Mechanism of action of this drug is:-
- A. Inhibiting intestinal absorption of carbohydrates
- B. Release of insulin acting as agonist of GLP-1 receptors (Correct Answer)
- C. Stimulation of PPAR-gamma
- D. Inhibition of DPP-4
Insulin and Oral Hypoglycemic Agents Explanation: ***Release of insulin acting as agonist of GLP-1 receptors***
- **Exenatide** is a **glucagon-like peptide-1 (GLP-1) receptor agonist**, mimicking the action of endogenous GLP-1.
- This leads to glucose-dependent **insulin release**, suppression of **glucagon secretion**, delayed **gastric emptying**, and increased **satiety**, all contributing to improved glycemic control.
*Inhibition of DPP-4*
- This mechanism describes the action of **DPP-4 inhibitors** (e.g., sitagliptin, saxagliptin), which prevent the breakdown of endogenous GLP-1 and other **incretin hormones**.
- While both GLP-1 agonists and DPP-4 inhibitors target the incretin system, exenatide directly acts as an agonist, rather than preventing breakdown.
*Inhibiting intestinal absorption of carbohydrates*
- This mechanism describes drugs like **alpha-glucosidase inhibitors** (e.g., acarbose, miglitol), which delay carbohydrate absorption from the gut.
- Exenatide's primary action is not on carbohydrate absorption but rather on pancreatic hormone secretion and gastric emptying.
*Stimulation of PPAR-gamma*
- This mechanism describes **thiazolidinediones** (TZDs) like pioglitazone and rosiglitazone, which enhance **insulin sensitivity** by acting on **peroxisome proliferator-activated receptor-gamma (PPAR-gamma)** in adipose tissue.
- Exenatide belongs to a different class of antidiabetic drugs with a distinct mechanism of action.
Insulin and Oral Hypoglycemic Agents Indian Medical PG Question 10: Which of the following statements about sitagliptin is false?
- A. Used in type II diabetes mellitus
- B. Cannot be used orally (Correct Answer)
- C. Used in combination with other oral hypoglycemic agents
- D. All of the above statements are true
Insulin and Oral Hypoglycemic Agents Explanation: ***Cannot be used orally***
- This statement is **false** because **sitagliptin** is an **oral medication** approved for the treatment of type 2 diabetes mellitus.
- As a **DPP-4 inhibitor**, it is designed to be taken by mouth to increase incretin hormone levels.
*Used in type II diabetes mellitus*
- This statement is **true** as **sitagliptin** is a commonly prescribed **oral antidiabetic drug** for the management of type 2 diabetes.
- It works by inhibiting the enzyme **dipeptidyl peptidase-4 (DPP-4)**, which increases levels of **GLP-1** and **GIP** to enhance insulin secretion and reduce glucagon secretion.
*Used in combination with other oral hypoglycemic agents*
- This statement is **true** as **sitagliptin** is often used as **add-on therapy** with other oral hypoglycemic agents like **metformin** or a **sulfonylurea** when monotherapy is insufficient.
- This combination approach helps achieve better glycemic control by targeting different mechanisms of action.
*All of the above statements are true*
- This statement is **false** because the first statement "Cannot be used orally" is incorrect.
- Since sitagliptin is indeed an oral medication, not all the above statements are true, making this option incorrect.
More Insulin and Oral Hypoglycemic Agents Indian Medical PG questions available in the OnCourse app. Practice MCQs, flashcards, and get detailed explanations.
